Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.
A brain volume quantification tool that may provide early insights on neurodegenerative conditions based on magnetic resonance imaging (MRI) assessment, the artificial intelligence (AI)-enabled NeuroShield has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Currently being utilized in over 200 facilities across the world, NeuroShield offers automated brain volume assessment based upon 3D MRI scans, according to InMed.AI (InMed Prognostics), the developer of NeuroShield.
The company noted that the brain segmentation analysis provided with NeuroShield has demonstrated high accuracy rates across different clinical subgroups and magnetic strengths in a trial of 280 subjects. InMed.AI noted that NeuroShield may aid in the early detection of brain atrophy, possibly facilitating timely intervention for those at risk of dementia, Alzheimer’s disease and other neurodegenerative conditions.
“We believe that investing in our collective human future and that technology is a great lever to move towards precision health to extend quality of life,” added Latha Poonamallee, Ph.D., the founder and CEO of InMed Prognostics.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
